XOMA Royalty (NASDAQ:XOMA) Share Price Passes Above 200 Day Moving Average - Should You Sell?

Key Points

• XOMA Royalty stock recently crossed above its 200-day moving average of $26.06, trading as high as $37.83, reflecting increased investor confidence.
• Analysts have shown a positive outlook for XOMA, with one firm raising its rating to "strong-buy" and setting a price target of $104.00, significantly above the current trading price.
• The company's latest earnings report revealed an EPS of $0.48, surpassing the consensus estimate by $0.60, indicating stronger-than-expected financial performance.

XOMA Royalty Corporation (NASDAQ:XOMA - Get Free Report) shares crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $26.06 and traded as high as $37.83. XOMA Royalty shares last traded at $36.70, with a volume of 125,719 shares.

Analysts Set New Price Targets

XOMA has been the subject of a number of analyst reports. Zacks Research upgraded XOMA Royalty from a "hold" rating to a "strong-buy" rating in a report on Wednesday, September 10th. HC Wainwright reiterated a "buy" rating and set a $104.00 target price on shares of XOMA Royalty in a research note on Wednesday, May 28th. Finally, Wall Street Zen upgraded XOMA Royalty from a "hold" rating to a "buy" rating in a research note on Monday, August 11th. One equities research analyst has rated the stock with a Strong Buy rating and two have given a Buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Buy" and an average price target of $69.50.

XOMA Royalty Price Performance

The company has a quick ratio of 4.88, a current ratio of 4.88 and a debt-to-equity ratio of 1.41. The company has a market capitalization of $439.41 million, a P/E ratio of -23.21 and a beta of 0.98. The business has a 50 day simple moving average of $30.91 and a 200-day simple moving average of $26.12.

XOMA Royalty (NASDAQ:XOMA - Get Free Report) last issued its quarterly earnings results on Wednesday, August 13th. The biotechnology company reported $0.48 EPS for the quarter, beating analysts' consensus estimates of ($0.12) by $0.60. The company had revenue of $13.13 million for the quarter, compared to analyst estimates of $9.39 million. XOMA Royalty had a positive return on equity of 2.63% and a negative net margin of 27.57%. Analysts predict that XOMA Royalty Corporation will post -1.41 EPS for the current fiscal year.

Institutional Investors Weigh In On XOMA Royalty

Institutional investors have recently made changes to their positions in the company. GAMMA Investing LLC lifted its holdings in shares of XOMA Royalty by 1,063.8% during the 1st quarter. GAMMA Investing LLC now owns 1,734 shares of the biotechnology company's stock valued at $35,000 after buying an additional 1,585 shares during the last quarter. Tower Research Capital LLC TRC lifted its holdings in shares of XOMA Royalty by 203.1% during the 2nd quarter. Tower Research Capital LLC TRC now owns 2,273 shares of the biotechnology company's stock valued at $57,000 after buying an additional 1,523 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of XOMA Royalty by 13.9% during the 2nd quarter. JPMorgan Chase & Co. now owns 4,440 shares of the biotechnology company's stock valued at $112,000 after buying an additional 543 shares during the last quarter. Raymond James Financial Inc. acquired a new stake in XOMA Royalty in the 2nd quarter worth approximately $116,000. Finally, Deutsche Bank AG lifted its holdings in XOMA Royalty by 5,087.9% in the 1st quarter. Deutsche Bank AG now owns 6,433 shares of the biotechnology company's stock worth $128,000 after purchasing an additional 6,309 shares during the last quarter. 95.92% of the stock is currently owned by institutional investors and hedge funds.

About XOMA Royalty

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.